Skip to main content
SpringerLink
Log in

ASH Update 2013: chronic lymphocytic leukemia and indolent lymphoma

  • short review
  • Published:
memo - Magazine of European Medical Oncology Aims and scope Submit manuscript

Abstract

At the annual meeting of the American Society of Hematology 2013, the focus in the field of chronic lymphocytic leukemia (CLL) and indolent lymphomas was again dominated by compelling data generated in clinical trials exploring the use of novel drugs targeting the B-cell receptor pathway. The results observed in early trials, e.g., with the Bruton’s tyrosine kinase inhibitor ibrutinib (formerly PCI-32765) and PI3Kδ inhibitor idelalisib (formerly CAL-101) have been consolidated. In view of these data, new clinical standards have been set up for the treatment of relapsed/refractory CLL. However, with the presentation of several randomized trials new standards concerning the use of immunochemotherapy are being suggested underscoring the importance of immunochemotherapeutic strategies despite the upcoming era of tyrosine kinase inhibitor treatment of CLL and indolent lymphoma.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Goede V, Fischer K, Busch R, et al. Head-to-head comparison of obinutuzumab (GA101) plus chlorambucil (Clb) versus rituximab plus Clb in patients with chronic lymphocytic leukemia (CLL) and co-existing medical conditions (comorbidities): final stage 2 results of the CLL11 trial [abstract]. Blood. 2013;122:6.

    Article  Google Scholar 

  2. Hillmen P, Robak T, Janssens A, et al. Ofatumumab + chlorambucil versus chlorambucil alone in patients with untreated chronic lymphocytic leukemia (CLL): results of the phase III study complement 1 (OMB110911) [abstract]. Blood. 2013;122:528.

    Google Scholar 

  3. Eichhorst B, Fink AM, Busch R, et al. Chemoimmunotherapy with fludarabine (F), cyclophosphamide (C), and rituximab (FCR) versus bendamustine and rituximab (BR) in previously untreated and physically fit patients (pts) with advanced chronic lymphocytic leukemia (CLL): results of a planned interim analysis of the CLL10 trial, an international, randomized study of the German CLL study group (GCLLSG) [abstract]. Blood. 2013;122:526.

    Google Scholar 

  4. Davis RE, Ngo VN, Lenz G, et al. Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. Nature. 2010;463:88–92.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  5. O’Brien S, Burger JA, Blum KA, et al. The Bruton’s tyrosine kinase (BTK) inhibitor PCI-32765 induces durable responses in relapsed or refractory (r/r) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): follow-up of a phase Ib/II study [abstract]. Blood. 2011;118:983.

    Google Scholar 

  6. Burger JA, Keating MJ, Wierda WG, et al. Ibrutinib in combination with rituximab (iR) is well tolerated and induces a high rate of durable remissions in patients with high-risk chronic lymphocytic leukemia (CLL): new, updated results of a phase II trial in 40 patients [abstract]. Blood. 2013;122:675.

    Google Scholar 

  7. Brown JR, Barrientos JC, Barr PM, et al. Ibrutinib in combination with bendamustine and rituximab is active and tolerable in patients with relapsed/refractory CLL/SLL: final results of a phase 1b study [abstract]. Blood. 2013;122:525.

    Google Scholar 

  8. Fischer K, Cramer P, Busch R, et al. Bendamustine combined with rituximab in patients with relapsed and/or refractory chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol. 2011;29:3559–66.

    Article  PubMed  CAS  Google Scholar 

  9. Furman R, Sharman JP, Coutre SE, et al. A phase 3, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of idelalisib and rituximab for previously treated patients with chronic lymphocytic leukemia (CLL). Blood. 2013;122.

  10. Seymour JF, Davids MS, Pagel JM, et al. Bcl-2 inhibitor ABT-199 (GDC-0199) monotherapy shows anti-tumor activity including complete remissions in high-risk relapsed/refractory (r/r) chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) [abstract]. Blood. 2013;122:872.

    Article  Google Scholar 

  11. Gopal A, Kahl BS, De Vos S, et al. Mature response data from a phase 2 study of PI3K-delta inhibitor idelalisib in patients with double (rituximab and alkylating agent)-refractory indolent B-cell non-Hodgkin lymphoma (iNHL) [abstract]. Blood. 2013;122:85.

    Google Scholar 

  12. Treon SP, Xu L, Yang G, et al. MYD88 L265P in Waldenström macroglobulinemia, immunoglobulin M monoclonal gammopathy, and other B-cell lymphoproliferative disorders using conventional and quantitative allele-specific polymerase chain reaction. N Engl J Med. 2012;367:826–33.

    Article  PubMed  CAS  Google Scholar 

  13. Yang G, Zhou Y, Liu X, et al. A mutation in MYD88 (L265P) supports the survival of lymphoplasmacytic cells by activation of Bruton tyrosine kinase in Waldenström macroglobulinemia. Blood. 2013;122:1222–32.

    Article  PubMed  CAS  Google Scholar 

  14. Treon SP, Tripsas CK, Yang G, et al. A prospective multicenter study of the Bruton’s tyrosine kinase inhibitor ibrutinib in patients with relapsed or refractory Waldenstrom’s macroglobulinemia [abstract]. Blood. 2013;122:251.

    Article  Google Scholar 

Download references

Conflict of interest

The author declares that there are no actual or potential conflicts of interest in relation to this article.

Author information

Authors and Affiliations

  1. Laboratory for Molecular Genetics & Diagnostics, Department of Internal Medicine V, Innsbruck Medical University, Anichstr. 35, 6020, Innsbruck, Austria

    Michael Steurer MD

Authors
  1. Michael Steurer MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Michael Steurer MD.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Steurer, M. ASH Update 2013: chronic lymphocytic leukemia and indolent lymphoma. memo 7, 141–143 (2014). https://doi.org/10.1007/s12254-014-0174-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12254-014-0174-4

Keywords

Search

Navigation